ECSP23019518A - Derivados de tetrahidroisoquinolina para el tratamiento de eritrocitos y enfermedades inflamatorias - Google Patents

Derivados de tetrahidroisoquinolina para el tratamiento de eritrocitos y enfermedades inflamatorias

Info

Publication number
ECSP23019518A
ECSP23019518A ECSENADI202319518A ECDI202319518A ECSP23019518A EC SP23019518 A ECSP23019518 A EC SP23019518A EC SENADI202319518 A ECSENADI202319518 A EC SENADI202319518A EC DI202319518 A ECDI202319518 A EC DI202319518A EC SP23019518 A ECSP23019518 A EC SP23019518A
Authority
EC
Ecuador
Prior art keywords
inflammatory diseases
erythrocytes
treatment
tetrahydroisoquinoline derivatives
diseases
Prior art date
Application number
ECSENADI202319518A
Other languages
English (en)
Inventor
Claude Barberis
George Karageorge
Kristen Terranova
John Jurcak
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP23019518A publication Critical patent/ECSP23019518A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan en la presente compuestos y composiciones de los mismos para activar el factor 2 relacionado con el factor 2 nuclear eritroide (Nrf2) para tratar las enfermedades de los eritrocitos y enfermedades inflamatorias.
ECSENADI202319518A 2020-09-14 2023-03-16 Derivados de tetrahidroisoquinolina para el tratamiento de eritrocitos y enfermedades inflamatorias ECSP23019518A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063078118P 2020-09-14 2020-09-14
US202163229338P 2021-08-04 2021-08-04

Publications (1)

Publication Number Publication Date
ECSP23019518A true ECSP23019518A (es) 2023-06-30

Family

ID=78080553

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202319518A ECSP23019518A (es) 2020-09-14 2023-03-16 Derivados de tetrahidroisoquinolina para el tratamiento de eritrocitos y enfermedades inflamatorias

Country Status (17)

Country Link
US (1) US20230357270A1 (es)
EP (1) EP4211134A1 (es)
JP (1) JP2023544089A (es)
KR (1) KR20230104126A (es)
CN (1) CN116406364A (es)
AU (1) AU2021340890A1 (es)
BR (1) BR112023004567A2 (es)
CA (1) CA3194774A1 (es)
CL (1) CL2023000732A1 (es)
CO (1) CO2023003083A2 (es)
CR (1) CR20230158A (es)
DO (1) DOP2023000050A (es)
EC (1) ECSP23019518A (es)
IL (1) IL301170A (es)
MX (1) MX2023003036A (es)
PE (1) PE20231363A1 (es)
WO (1) WO2022056448A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4688779A2 (en) * 2023-04-03 2026-02-11 Acelink Therapeutics, Inc. Novel compounds and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102301867B1 (ko) * 2013-12-18 2021-09-15 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Nrf2 조절제
US20190389836A1 (en) * 2017-01-30 2019-12-26 Biogen Ma Inc. Nrf2 activator
JP2020097526A (ja) * 2017-03-28 2020-06-25 武田薬品工業株式会社 複素環化合物
NZ776102A (en) * 2018-12-05 2024-12-20 Scohia Pharma Inc Macrocyclic compound and use thereof

Also Published As

Publication number Publication date
CL2023000732A1 (es) 2023-10-30
PE20231363A1 (es) 2023-09-05
AU2021340890A9 (en) 2025-01-09
US20230357270A1 (en) 2023-11-09
AU2021340890A1 (en) 2023-05-04
CR20230158A (es) 2023-07-13
BR112023004567A2 (pt) 2023-04-04
MX2023003036A (es) 2023-06-21
CO2023003083A2 (es) 2023-06-30
KR20230104126A (ko) 2023-07-07
EP4211134A1 (en) 2023-07-19
DOP2023000050A (es) 2023-07-16
JP2023544089A (ja) 2023-10-20
IL301170A (en) 2023-05-01
WO2022056448A1 (en) 2022-03-17
CN116406364A (zh) 2023-07-07
CA3194774A1 (en) 2022-03-17

Similar Documents

Publication Publication Date Title
CL2022000751A1 (es) Inhibidores de la fosfatasa shp2 y métodos para su uso (divisional de la solicitud no. 202002419)
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CO2024006030A2 (es) Compuestos de quinolina como inhibidores de kras
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
AR002267A1 (es) Compuestos de imidazol utiles para el tratamiento de patologias mediadas por citoquinas; composicion farmaceutica que los contiene; proceso para preparar dichos compuestos; uso del mismo para preparar dichas composiciones; compuestos intermediarios y procesos para su preparacion.
CO2018013077A2 (es) Inhibidores de la arginasa y sus aplicaciones terapéuticas
MX2022013396A (es) Compuestos de tetrahidroisoquinolina como activadores de nrf2.
CL2023003531A1 (es) Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos.
MX2021004566A (es) Compuestos terapeuticos.
UY28317A1 (es) Compuestos útiles para el tratamiento de enfermedades
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
AR127470A1 (es) Inhibidores de lrrk2
MX2024015493A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1
ECSP23019518A (es) Derivados de tetrahidroisoquinolina para el tratamiento de eritrocitos y enfermedades inflamatorias
CO2024017422A2 (es) Composiciones y métodos para inhibir la expresión de serina proteasa transmembrana 6 (tmprss6)
MX2023013176A (es) Derivados espiro sustituidos.
MX2022013398A (es) Compuestos de tetrahidroisoquinolina como activadores de nrf2.
ES2106770T3 (es) Compuestos difenilicos como inhibidores del metabolismo del acido araquidonico y su empleo en composiciones farmaceuticas.
CL2021000282A1 (es) Inhibidores de ckd8/19
ES2112832T3 (es) Derivados carbamoilicos.
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")
AR132909A1 (es) Métodos de tratamiento de enfermedades inflamatorias